Breaking News: FDA Approves Two New Treatments for Atopic Dermatitis: Biologic Nemluvio and Topical Cream Vtama

The eczema community continues to expand its treatment options with the approval of two new medications in late 2024:

• A new biologic. On December 13, the U.S. Food and Drug Administration (FDA) approved Nemluvio (nemolizumab-ilto), an IL-31 inhibitor biologic developed by Galderma for people ages 12 and older with moderate to severe atopic dermatitis, in combination with topical corticosteroids (TCS) and/or calcineurin inhibitors (TCI), whose disease is not adequately controlled with topical prescription therapies.  
• A new nonsteroidal topical. On December 16, the FDA approved Vtama (tapinarof) cream (1%), an aryl hydrocarbon receptor agonist and nonsteroidal topical cream from manufacturer Dermavant, an Organon company, for the treatment of atopic dermatitis in adults and children 2 years of age and older. 

It’s important to talk to your doctor about how atopic dermatitis affects your skin and other aspects of your life. Together, you and your healthcare provider can determine which treatment option might be right for you.

Learn more about Nemluvio and Vtama and visit our New Prescription Treatment hub to find out about other new therapies as they are available.